Events in 2023

CONGRESS 2023 - How to avoid pitfalls and pass the HSD

27/09/2023
The Higher Specialist Diploma (HSD) is the main route for gaining Fellowship (FIBMS) status. In this session I will provide a brief overview of the IBMS Higher Specialist Diploma (HSD) qualification explaining the disciplines that the HSD can be undertaken in, who the qualification is aimed at and how the qualification is assessed.

I will then provide advice and guidance on the completion of the portfolio element of the qualification and explain what a good portfolio looks like. I will also briefly explain how to prepare for the exam element of the qualification. There will also be an opportunity to ask questions about the HSD.

CONGRESS 2023 - Mismatch Repair (MMR): Ten years of EQA experience

27/09/2023
Delegates attending this presentation will:

Receive an overview of the clinical history of MMR/Lynch Syndrome, EQA and data from UK NEQAS ICC & ISH
Gain a better understanding of the importance of MMR testing and the UK NEQAS ICC & ISH assessment process.
The presentation will also focus on acceptable and not acceptable tests, and the importance of ideal controls.

CONGRESS 2023 - Evolution of infectious disease Point-of-Care Testing (POCT) across Wales - National POCT Lead perspective

27/09/2023
Learn how infectious disease POCT services have evolved across Wales. Discover how Louise's role as a Biomedical Scientist has evolved to National infectious disease POCT lead. Discover how POCT projects are contributing towards the World Health Organisations Hepatitis C elimination targets and how we foresee future POCT services expanding.

CONGRESS 2023 - Targeting HIV where it hurts - progress on vaccines

27/09/2023
Effective vaccine must deal with extreme HIV-1 variability and do so without guidance from natural immunity. For HIV-1, vaccines may need to induce both bNAbs and protective CD8+ killer T cells, the latter of which clearly impose a selective pressure on the virus and their protective potential should be harnessed by vaccines. However, not all antibodies and CD8+ T cells are protective; they must target vulnerable parts on HIV-1 proteins.

The central paradigm of the HIVconsvX T-cell vaccine strategy is focusing T cells on the functionally conserved regions of the HIV-1 Gag and Pol proteins, which are very similar among global isolates and harbour fewer escape mutations. At the epitope level, the remaining variability within the conserved regions is addressed computationally by using a bi-valent mosaic. Results of the first trials testing the HIVconsvX vaccine candidates confirmed that conserved sub-dominant and, therefore, underused T-cell epitopes taken out of the context of the whole virus or full-length viral proteins can induce robust and broad T-cell responses when delivered by an effective heterologous regimen such as ChAdOx1-MVA.

Progress towards an effective HIV-1 vaccine has been slow and riddled with many setbacks. However, systematic iterative development of vaccine components for both neutralizing antibodies and effective T cells informed by human data is beginning to pay off by bringing the first encouragements endorsing the field’s overall direction of travel.

CONGRESS 2023 - Reflection on a Journey from Trainee Biomedical Scientist to Consultant Clinical Scientist

27/09/2023
This presentation will give:

Training requirements for Biomedical Scientists and Clinical Scientists
Insight into how the skills of a Biomedical Scientist enabled development toward Consultant Clinical Scientist.

CONGRESS 2023 - Shared training – the Scottish Training Academy to Registration Portfolio training

27/09/2023
Shared training – the Scottish Training Academy to Registration Portfolio training

CONGRESS 2023 - Vaccines and immunodeficiency testing (Wednesday)

27/09/2023
A person's immune response to previous antigen exposure is one of the most useful measures of how well their immune system is functioning. Vaccination provides a controlled and standardised exposure to an antigen, with the ability to assess immune responses prior to and after exposure. Different vaccine types can be used to explore different aspects of immune function.

Traditionally, antibody levels have been used to interrogate these responses, and it is possible to explore the quality of the antibody response and also cellular responses. A wide variability in the response to vaccination in healthy individuals can complicate interpretation of vaccine responses in patients with recurrent infections. Protection from infection is multifactorial, and while our ability to assess vaccine responses is improving, this alone is often not enough to assess an individual's immunity.

CONGRESS 2023 - Generation X,Y,Z: Ageism in the workplace and its impact on service delivery

27/09/2023
Generation X,Y,Z: Ageism in the workplace and its impact on service delivery

CONGRESS 2023 - Iron Deficiency Polycythaemia: A Clinical Case Study

27/09/2023
A case study into iron deficiency polycythaemia diagnosis, looking at the pathology and how this relates to the results we see and investigations to confirm diagnosis.

CONGRESS 2023 - HR and OH departments – how to work with them to achieve the best results

27/09/2023
HR and OH departments – how to work with them to achieve the best results